We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Hemostasis Analyzers Market Driven by Increasing Awareness of Blood Disorder Conditions

By LabMedica International staff writers
Posted on 09 Feb 2023
Print article
Image: The global hemostasis analyzers market is expected to reach close to USD 6 billion in 2026 (Photo courtesy of Pexels)
Image: The global hemostasis analyzers market is expected to reach close to USD 6 billion in 2026 (Photo courtesy of Pexels)

Hemostasis analyzers are devices used for measuring clotting mechanisms of hemostasis in order to detect clotting deficiencies. The body’s natural ability to quickly stop bleeding in order to stop serious blood loss is known as hemostasis. Hemostasis analyzers are used to perform tests such as APTT tests, D dimer tests, platelet function tests, fibrinogen tests, prothrombin time tests, and other tests using optical technology, mechanical technology, electrochemical technology, and other technologies. Within hemostasis analyzers, the main products are clinical laboratory analyzers, point-of-care testing analyzers, and consumables. Clinical laboratory analyzers are used to calculate the concentration of certain substances in various samples. The various end users of hemostasis analyzers are hospitals and clinics, diagnostic centers, research and development organizations and ambulatory surgical centers, among others.

The global hemostasis analyzers market is expected to reach USD 5.97 billion in 2026, driven by the increasing awareness of blood disorder conditions such as Hemophilia and Von Willebrand disease (vWD) which are genetic disorders and not well known to people. This results in late diagnosis of blood disorders and affects patient outcomes. The increasing awareness is expected to improve the diagnosis rate of blood disorders, thereby driving the demand for hemostasis analyzers. However, recalls of defective devices could act as a restraint to the growth of the hemostasis analyzers market. These are the latest findings of ReportLinker (Lyon, France), a market research solution provider.

The hemostasis analyzers market consists of sales of complete blood count (CBC), factor v assay, fibrinogen level, prothrombin time (PT or PT-INR), platelet count, and thrombin time. Manufacturers of hemostasis analyzers are developing portable, handheld hemostasis analyzers which are convenient for carrying anywhere and are small enough to fit in a person's palm. These portable hemostasis analyzers offer a quicker and easier testing process, and facilitate independent analysis of results. Geographically, North America dominated the global hemostasis analyzers market in 2022 with the largest share, followed by Western Europe with the second-largest share.

Related Links:
ReportLinker 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more